US Pharma MarketingThe findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.
New Taiho, Cullinan data heats up lung cancer drug battle
The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.
Source: BioPharma Dive